title: Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis).
abstract: The safety, immunogenicity and efficacy of recombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccine in ISS/Montanide adjuvant-administered intramuscular (IM) was assessed in adult female cynomolgus macaques challenged with Coccidioides posadasii. Animals received three immunizations with either 5 microg CFP, 50-microg CFP, or adjuvant alone and were challenged 4 weeks following the final immunization. Although significant antibody response was produced in response to vaccination, there were no discernable adverse effects, suggesting that the vaccine was well tolerated. Upon intratracheal challenge, all animals showed evidence of disease. Two animals that received 5-microg doses of CFP were euthanatized prior to the study's end because of severe symptoms. Animals vaccinated with 50-microg doses of CFP showed evidence of enhanced sensitization compared to adjuvant controls and animals vaccinated with 5-microg doses of CFP. This was based on higher serum anti-CFP titers, enhanced secretion of interferon-gamma (IFN-gamma) from stimulated bronchoalveolar lavage mononuclear cells (BALMC), reduced pulmonary radiologic findings following intratracheal challenge, reduced terminal complement fixation titers, and reduced necropsy findings. Overall the vaccine was well tolerated, induced sensitization, and resulted in a protective response when given at the higher 50-microg dose. Additional experiments may be needed to optimize the vaccination and to confer greater protection against lethal challenge.
authors.affiliation: D.V.M. M.P.V.M., California National Primate Research Center, University of California, Davis, CA 95616, USA.
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Johnson
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Lerche
authors.forename: Demosthenes
authors.initials: D
authors.lastname: Pappagianis
authors.forename: Joann L
authors.initials: JL
authors.lastname: Yee
authors.forename: John N
authors.initials: JN
authors.lastname: Galgiani
authors.forename: Richard F
authors.initials: RF
authors.lastname: Hector
mesh_terms: D000818:Animals; D003047:Coccidioidomycosis / Q000378:metabolism / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D005260:Female; D005657:Fungal Vaccines / Q000737:chemistry*; D007107:Immune System; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008252:Macaca fascicularis; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D012449:Safety; D014614:Vaccines, Synthetic / Q000737:chemistry*
chemical_list: D005657:Fungal Vaccines; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D007371:Interferon-gamma